These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31756032)

  • 1. Quantitative assessment of adverse events in clinical trials: Comparison of methods at an interim and the final analysis.
    Hollaender N; Gonzalez-Maffe J; Jehl V
    Biom J; 2020 May; 62(3):658-669. PubMed ID: 31756032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risks.
    Stegherr R; Schmoor C; Beyersmann J; Rufibach K; Jehl V; Brückner A; Eisele L; Künzel T; Kupas K; Langer F; Leverkus F; Loos A; Norenberg C; Voss F; Friede T
    Trials; 2021 Jun; 22(1):420. PubMed ID: 34187527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): summary of findings and assessment of existing guidelines.
    Rufibach K; Beyersmann J; Friede T; Schmoor C; Stegherr R
    Trials; 2024 May; 25(1):353. PubMed ID: 38822392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical issues in the analysis of adverse events in time-to-event data.
    Allignol A; Beyersmann J; Schmoor C
    Pharm Stat; 2016 Jul; 15(4):297-305. PubMed ID: 26929180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-parametric inference of adverse events under informative censoring.
    Nishikawa M; Tango T; Ogawa M
    Stat Med; 2006 Dec; 25(23):3981-4003. PubMed ID: 16526008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonparametric inference on cause-specific quantile residual life.
    Jeong JH; Fine JP
    Biom J; 2013 Jan; 55(1):68-81. PubMed ID: 23065930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events in single-arm clinical trials with non-fatal time-to-event efficacy endpoint: from clinical questions to methods for statistical analysis.
    Tassistro E; Bernasconi DP; Valsecchi MG; Antolini L
    BMC Med Res Methodol; 2024 Jan; 24(1):3. PubMed ID: 38172810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating and comparing adverse event probabilities in the presence of varying follow-up times and competing events.
    Stegherr R; Schmoor C; Lübbert M; Friede T; Beyersmann J
    Pharm Stat; 2021 Nov; 20(6):1125-1146. PubMed ID: 34002935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved confidence intervals for a difference of two cause-specific cumulative incidence functions estimated in the presence of competing risks and random censoring.
    Scosyrev E
    Biom J; 2020 Oct; 62(6):1394-1407. PubMed ID: 32227361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competing risk bias in Kaplan-Meier risk estimates can be corrected.
    van Walraven C; Hawken S
    J Clin Epidemiol; 2016 Feb; 70():101-5. PubMed ID: 26327491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonparametric estimation for cumulative duration of adverse events.
    Wang J; Quartey G
    Biom J; 2012 Jan; 54(1):61-74. PubMed ID: 22170311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials.
    Basch E; Rogak LJ; Dueck AC
    Clin Ther; 2016 Apr; 38(4):821-30. PubMed ID: 27045992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semiparametric models for cumulative incidence functions.
    Bryant J; Dignam JJ
    Biometrics; 2004 Mar; 60(1):182-90. PubMed ID: 15032788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of adverse event reporting in companion animal clinical trials evaluating cancer treatment.
    Giuffrida MA
    J Am Vet Med Assoc; 2016 Nov; 249(9):1079-1087. PubMed ID: 27767430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.
    Campone M; Yang H; Faust E; Kageleiry A; Signorovitch JE; Zhang J; Gao H
    J Med Econ; 2014 Dec; 17(12):837-45. PubMed ID: 25164472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A note on competing risks in survival data analysis.
    Satagopan JM; Ben-Porat L; Berwick M; Robson M; Kutler D; Auerbach AD
    Br J Cancer; 2004 Oct; 91(7):1229-35. PubMed ID: 15305188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse event reporting in publications compared with sponsor database for cancer clinical trials.
    Scharf O; Colevas AD
    J Clin Oncol; 2006 Aug; 24(24):3933-8. PubMed ID: 16921045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ignoring competing events in the analysis of survival data may lead to biased results: a nonmathematical illustration of competing risk analysis.
    Schuster NA; Hoogendijk EO; Kok AAL; Twisk JWR; Heymans MW
    J Clin Epidemiol; 2020 Jun; 122():42-48. PubMed ID: 32165133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonparametric estimation of the survival function for ordered multivariate failure time data: A comparative study.
    Meira-Machado L; Sestelo M; Gonçalves A
    Biom J; 2016 May; 58(3):623-34. PubMed ID: 26455826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.
    Irwin DE; Masaquel A; Johnston S; Barnett B
    J Med Econ; 2016 Nov; 19(11):1027-1033. PubMed ID: 27206801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.